CIRM Funded Clinical Trials

Safety and Feasibility of Cultivated Autologous Limbal Stem Cells for Limbal Stem Cell Deficiency


Disease Area:
Corneal Damage
Investigator:
Dr. Sophie X Deng
Institution:
University of California, Los Angeles
CIRM Grant:
CLIN2-11650 (Active)
Award Value:
$10,301,486.00
Trial Sponsor:
University of California, Los Angeles
Trial Stage:
Phase 1
Trial Status:
Recruiting
Targeted Enrollment:
20
ClinicalTrials.gov ID:
NCT03957954

Details:

Limbal stem cell deficiency (LSCD) is a blinding corneal disease. LSCD is caused by a decrease in the number and/or function of limbal stem cells (LSCs), a type of stem cell that is needed to continuously regenerate tissue of the cornea, the clear front surface of the eye that refracts light entering the eye and is responsible for the majority of the optical power.  Without adequate limbal cells , inflammation, scarring, eye pain, loss of corneal clarity and gradual vision loss can occur.  This clincial trial will expand the patient’s own remaining LSCs for transplantation and will use novel diagnostic methods to assess the severity of LSCD and patient responses to treatment.

Design:

Phase 1 Trial 

Goal:

This trial will collect preliminary information on the activity and safety of the treatment. 

CIRM Clinical Trial Resources

Patient Stories of Hope

CIRM Alpha Stem Cell Clinics

Patient Toolbox

Video on Stem Cell Trials

Other Resources

ISSCR Patient Website

ClinicalTrials.gov